Abstract
In a few cases, gemcitabine (GCB) has been shown to result in systemic capillary leak syndrome (SCLS) in the treatment of non-small cell lung, pancreatic, and ovarian carcinomas. SCLS is a life-threatening condition characterized by increased capillary permeability resulting in manifest pulmonary and peripheral edema. Usually SCLS responds successfully to corticosteroid therapy and diuretics. We present a case where GCB treatment likely resulted in SCLS in a male patient with metastatic renal cell carcinoma (RCC) in the absence of predisposing cardiac, pleural, or pulmonary disease.
MeSH terms
-
Biopsy, Needle
-
Capillary Leak Syndrome / chemically induced*
-
Capillary Leak Syndrome / physiopathology
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / pathology*
-
Carcinoma, Renal Cell / secondary
-
Carcinoma, Renal Cell / surgery
-
Chemotherapy, Adjuvant
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects*
-
Deoxycytidine / analogs & derivatives*
-
Gemcitabine
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology*
-
Kidney Neoplasms / surgery
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Nephrectomy / methods
-
Pulmonary Edema / chemically induced
-
Pulmonary Edema / physiopathology
-
Risk Assessment
-
Severity of Illness Index
Substances
-
Deoxycytidine
-
Gemcitabine